MCID: SJG008
MIFTS: 61

Sjogren Syndrome

Categories: Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Sjogren Syndrome

MalaCards integrated aliases for Sjogren Syndrome:

Name: Sjogren Syndrome 56 12 52 36 17
Sjogren's Syndrome 12 25 42 43 15 71
Sicca Syndrome 56 12 52 25 71
Keratoconjunctivitis Sicca 25 71
Sjogren-Gougerot Syndrome 52 25
Sjögren's Syndrome 74 53
Keratoconjunctivitis Sicca-Xerostomia 25
Secreto-Inhibitor-Xerodermostenosis 25
Dacryosialoadenopathia Atrophicans 25
Primary Sjogren-Gougerot Syndrome 58
Gougerot-Houwer-Sjogren Syndrome 25
Gougerot-Sjogren Syndrome 25
Sjogrens Syndrome Primary 54
Primary Sjogren Syndrome 58
Dry Eye Syndromes 71
Sjogrens Syndrome 54
Xerodermosteosis 12
Sjögren Syndrome 25

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
sjogren syndrome:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases


Summaries for Sjogren Syndrome

Genetics Home Reference : 25 Sjögren syndrome is a disorder whose main features are dry eyes and a dry mouth. The condition typically develops gradually beginning in middle adulthood, but it can occur at any age. Sjögren syndrome is classified as an autoimmune disorder, one of a large group of conditions that occur when the immune system attacks the body's own tissues and organs. In Sjögren syndrome, the immune system primarily attacks the glands that produce tears (the lacrimal glands) and saliva (the salivary glands), impairing the glands' ability to secrete these fluids. Dry eyes may lead to itching, burning, a feeling of sand in the eyes, blurry vision, or intolerance of bright or fluorescent lighting. A dry mouth can feel chalky or full of cotton, and affected individuals may have difficulty speaking, tasting food, or swallowing. Because saliva helps protect the teeth and the tissues of the oral cavity, people with Sjögren syndrome are at increased risk of tooth decay and infections in the mouth. In most people with Sjögren syndrome, dry eyes and dry mouth are the primary features of the disorder, and general health and life expectancy are largely unaffected. However, in some cases the immune system also attacks and damages other organs and tissues. This complication is known as extraglandular involvement. Affected individuals may develop inflammation in connective tissues, which provide strength and flexibility to structures throughout the body. Disorders involving connective tissue inflammation are sometimes called rheumatic conditions. In Sjögren syndrome, extraglandular involvement may result in painful inflammation of the joints and muscles; dry, itchy skin and skin rashes; chronic cough; a hoarse voice; kidney and liver problems; numbness or tingling in the hands and feet; and, in women, vaginal dryness. Prolonged and extreme tiredness (fatigue) severe enough to affect activities of daily living may also occur in this disorder. A small number of people with Sjögren syndrome develop lymphoma, a blood-related cancer that causes tumor formation in the lymph nodes. Some individuals who are first diagnosed with another rheumatic disorder, such as rheumatoid arthritis or systemic lupus erythematosus, later develop the dry eyes and dry mouth characteristic of Sjögren syndrome. Other autoimmune disorders can also develop after the onset of Sjögren syndrome. In all, about half of all individuals with Sjögren syndrome also have another autoimmune disorder.

MalaCards based summary : Sjogren Syndrome, also known as sjogren's syndrome, is related to aplasia of lacrimal and salivary glands and salivary gland disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Sjogren Syndrome is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Toll-like receptor signaling pathway and JAK-STAT signaling pathway. The drugs Sodium citrate and Glycerol have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and skin, and related phenotypes are xerostomia and keratoconjunctivitis sicca

Disease Ontology : 12 An autoimmune hypersensitivity disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva.

NIH Rare Diseases : 52 Sjogren syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjogren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus . The hallmark symptoms of Sjogren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Treatment focuses on the symptoms in each person and may include moisture replacement therapies, nonsteroidal anti-inflammatory drugs and, in severe cases, corticosteroids or immunosuppressive drugs.

OMIM : 56 Sjogren syndrome is an autoimmune disease that mainly affects the exocrine glands. It is clinically characterized by keratoconjunctivitis sicca and xerostomia (Goransson et al., 2006). See 200400 for association of Sjogren syndrome with achalasia in sisters. (270150)

MedlinePlus : 42 Sjogren's syndrome is an autoimmune disease. This means that your immune system attacks parts of your own body by mistake. In Sjogren's syndrome, it attacks the glands that make tears and saliva. This causes a dry mouth and dry eyes. You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves. Most people with Sjogren's syndrome are women. It usually starts after age 40. It is sometimes linked to other diseases such as rheumatoid arthritis and lupus. To make a diagnosis, doctors may use a medical history, physical exam, certain eye and mouth tests, blood tests, and biopsies. Treatment focuses on relieving symptoms. It can differ for each person; it depends on what parts of the body are affected. It may include artificial tears for dye eyes and sucking on sugar-free candy or drinking water often for a dry mouth. Medicines may help with severe symptoms. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 53 Sjögren's syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren's syndrome is also associated with rheumatic disorders such as rheumatoid arthritis. The hallmark symptoms of the disorder are dry mouth and dry eyes. In addition, Sjogren's syndrome may cause skin, nose, and vaginal dryness, and may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Sjögren's syndrome affects 1-4 million people in the United States. Most people are more than 40 years old at the time of diagnosis. Women are 9 times more likely to have Sjögren's syndrome than men.

KEGG : 36 Sjogren Syndrome (SS) is a chronic inflammatory systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands leading to sicca symptoms of the eyes and mouth. Several systemic and extraglandular manifestations can develop, including fatigue, arthritis, and involvement of organs such as the skin, lungs, and kidneys. SS may occur as a primary disorder or in association with other systemic autoimmune diseases, traditionally defined as secondary SS, such as rheumatoid arthritis, and systemic lupus erythematosus. Salivary secretions from these patients exhibit elevated levels of antibodies and cytokines. This is accompanied by a reduction in oral phosphate levels and xerostomia due to reduced salivary flow, which can lead to infections, progressive caries, dysphagia and oral pain. Current tests for SS include sialometry, salivary scintigraphy, sialography, serological tests or minor salivary gland biopsies. Recently, salivary biomarkers of SS has been investigated. The etiology of SS is still unclear. Since there is a familial aggregation of primary SS, however, genetic factors have been suspected for a long time. Initially, HLA haplotypes were shown to be associated with primary SS. Recently, polymorphisms in the genes IRF5 and STAT4 have been convincingly identified and replicated in several studies as susceptibility factors.

Wikipedia : 74 Sjögren syndrome (SjS, SS) is a long-term autoimmune disease that affects the body's moisture-producing... more...

Related Diseases for Sjogren Syndrome

Diseases in the Sjogren Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease

Diseases related to Sjogren Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1229)
# Related Disease Score Top Affiliating Genes
1 aplasia of lacrimal and salivary glands 32.4 SPTAN1 HSPG2 CHRM3
2 salivary gland disease 32.4 TRIM21 TNFSF13B SSB LTF
3 diffuse infiltrative lymphocytosis syndrome 30.9 TRIM21 SSB
4 purpura 30.9 TNFSF13B CD79A APOH
5 neonatal lupus erythematosus 30.8 TRIM21 SPTAN1
6 autoimmune disease 30.8 TRIM21 TNFSF13B RO60 IL2RA FASLG FAS
7 mononeuritis multiplex 30.7 TRIM21 SSB
8 atrioventricular block 30.7 TRIM21 SSB RO60
9 xerophthalmia 30.7 TRIM21 TNFSF13B SSB SPTAN1 RO60 HSPG2
10 type ii mixed cryoglobulinemia 30.7 FASLG FAS
11 lupus erythematosus 30.7 TRIM21 SSB RO60 FASLG APOH
12 polyclonal hypergammaglobulinemia 30.6 TRIM21 TNFSF13B SSB
13 cryoglobulinemia 30.6 TNFSF13B CD79A APOH
14 collagen disease 30.6 TRIM21 HSPG2 APOH
15 parotitis 30.6 TRIM21 SSB LTF CD79A
16 dacryoadenitis 30.5 SPTAN1 HSPG2
17 hashimoto thyroiditis 30.5 IL2RA IFNG-AS1 FASLG FAS
18 syphilis 30.5 FAS CD79A APOH
19 heart block, congenital 30.5 TRIM21 SSB RO60 APOH
20 mixed connective tissue disease 30.5 TNFSF13B HSPG2 APOH
21 hyperglobulinemic purpura 30.5 TRIM21 TNFSF13B HSPG2
22 keratoconjunctivitis sicca 30.5 TRIM21 TNFSF13B SSB SPTAN1 RO60 LTF
23 sialadenitis 30.4 TRIM21 TNFSF13B SSB SPTAN1 RO60 HSPG2
24 vasculitis 30.4 TNFSF13B LTF CD79A APOH
25 immune deficiency disease 30.4 TNFSF13B IL2RA FASLG FAS CD79A
26 dry eye syndrome 30.4 TRIM21 SSB LTF
27 lymphadenitis 30.4 IL2RA FASLG FAS
28 chronic graft versus host disease 30.4 TNFSF13B IL2RA CD79A
29 limited scleroderma 30.3 TRIM21 SSB SPTAN1 RO60 IL2RA
30 cutaneous lupus erythematosus 30.3 TRIM21 TNFSF13B RO60
31 root caries 30.3 LTF CD79A
32 lymphoid interstitial pneumonia 30.2 TRIM21 SSB HSPG2
33 common variable immunodeficiency 30.2 TNFSF13B IL2RA FAS CD79A
34 thrombocytopenia 30.2 TNFSF13B FASLG FAS CD79A APOH
35 parotid disease 30.2 TRIM21 SSB
36 lymphocytic gastritis 30.1 FASLG FAS
37 severe cutaneous adverse reaction 30.1 HSPG2 FASLG FAS
38 lymphoproliferative syndrome 30.0 IL2RA FASLG FAS
39 behcet syndrome 30.0 TNFSF13B IL2RA HSPG2 FAS APOH
40 tetanus 29.9 IL2RA FASLG CD79A
41 rheumatoid arthritis 29.8 TNFSF13B IL2RA FASLG FAS CD79A APOH
42 systemic lupus erythematosus 29.8 TRIM21 TNFSF13B SSB RO60 LTF IL2RA
43 third-degree atrioventricular block 29.5 TRIM21 SSB
44 marinesco-sjogren syndrome 12.8
45 sjogren's syndrome, juvenile, secondary to autoimmune disease 12.3
46 reynolds syndrome 11.6
47 distal renal tubular acidosis 11.5
48 autoimmune inner ear disease 11.5
49 systemic scleroderma 11.5
50 retrovirus-associated myelopathy 11.5

Comorbidity relations with Sjogren Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypothyroidism Ichthyosis Vulgaris
Osteoporosis Postinflammatory Pulmonary Fibrosis
Rheumatoid Arthritis Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Sjogren Syndrome:



Diseases related to Sjogren Syndrome

Symptoms & Phenotypes for Sjogren Syndrome

Human phenotypes related to Sjogren Syndrome:

58 31 (show top 50) (show all 83)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 xerostomia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000217
2 keratoconjunctivitis sicca 58 31 hallmark (90%) Very frequent (99-80%) HP:0001097
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
5 anxiety 58 31 frequent (33%) Frequent (79-30%) HP:0000739
6 tubulointerstitial nephritis 58 31 frequent (33%) Frequent (79-30%) HP:0001970
7 parotitis 58 31 frequent (33%) Frequent (79-30%) HP:0011850
8 chronic pain 58 31 frequent (33%) Frequent (79-30%) HP:0012532
9 polyarticular arthropathy 58 31 frequent (33%) Frequent (79-30%) HP:0005195
10 usual interstitial pneumonia 58 31 frequent (33%) Frequent (79-30%) HP:0031950
11 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
12 muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0001324
13 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
14 dry skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0000958
15 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
16 myalgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003326
17 myositis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100614
18 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
19 vitiligo 58 31 occasional (7.5%) Occasional (29-5%) HP:0001045
20 thyroiditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100646
21 biliary cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002613
22 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
23 lymphoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002665
24 purpura 58 31 occasional (7.5%) Occasional (29-5%) HP:0000979
25 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
26 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
27 abnormal cerebellum morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001317
28 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
29 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
30 sensory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0003474
31 optic neuritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100653
32 functional motor deficit 58 31 occasional (7.5%) Occasional (29-5%) HP:0004302
33 raynaud phenomenon 58 31 occasional (7.5%) Occasional (29-5%) HP:0030880
34 bronchitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012387
35 lymphoproliferative disorder 58 31 occasional (7.5%) Occasional (29-5%) HP:0005523
36 normocytic anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001897
37 cryoglobulinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100778
38 decreased serum complement c3 58 31 occasional (7.5%) Occasional (29-5%) HP:0005421
39 glomerulonephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000099
40 erythema nodosum 58 31 occasional (7.5%) Occasional (29-5%) HP:0012219
41 arteritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012089
42 decreased serum complement c4 58 31 occasional (7.5%) Occasional (29-5%) HP:0045042
43 normochromic anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001895
44 nonproductive cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0031246
45 lichenoid skin lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0031452
46 abnormal pulmonary thoracic imaging finding 58 31 occasional (7.5%) Occasional (29-5%) HP:0031983
47 lymphoid interstitial pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0006527
48 vaginal dryness 58 31 occasional (7.5%) Occasional (29-5%) HP:0031088
49 abnormality of the peripheral nervous system 58 31 occasional (7.5%) Occasional (29-5%) HP:0410008
50 seizure 31 occasional (7.5%) HP:0001250

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Mouth:
xerostomia

Immunology:
autoimmune disease

Head And Neck Eyes:
xerophthalmia, more severe in men

Skeletal:
rheumatoid arthritis

Genitourinary Kidneys:
interstitial nephritis

Clinical features from OMIM:

270150

UMLS symptoms related to Sjogren Syndrome:


back pain, sciatica, muscle cramp, eye manifestations, dryness of eye

GenomeRNAi Phenotypes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.4 CD79A CHRM3 LTF
2 Decreased viability GR00381-A-1 9.4 CD79A CHRM3 LTF
3 Decreased viability GR00381-A-3 9.4 CD79A CHRM3 LTF
4 Decreased viability GR00386-A-1 9.4 CD79A CHRM3
5 Decreased viability GR00402-S-2 9.4 LTF

Drugs & Therapeutics for Sjogren Syndrome

Drugs for Sjogren Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Glycerol Approved, Investigational Phase 4 56-81-5 753
3
Dimenhydrinate Approved Phase 4 523-87-5 441281
4
Povidone Approved Phase 4 9003-39-8
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Dipivefrin Approved Phase 4 52365-63-6 3105
11 sodium fluoride Approved Phase 4 7681-49-4
12
Allantoin Approved Phase 4 97-59-6 204
13
Ethanol Approved Phase 4 64-17-5 702
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
16
Travoprost Approved Phase 4 157283-68-6 5282226
17
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
18
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
19
Menthol Approved Phase 4 2216-51-5 16666
20
Sorbitol Approved Phase 4 50-70-4 5780
21
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
22
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
23
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
24
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
25
Calcium carbonate Approved, Investigational Phase 4 471-34-1
26
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
27
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
28
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
29
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
30 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
31
Ocrelizumab Approved, Investigational Phase 4 637334-45-3
32
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
33
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
35
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
37
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
39
Betaine Approved, Nutraceutical Phase 4 107-43-7 247
40 Tocotrienol Investigational Phase 4 6829-55-6
41 Gallopamil Investigational Phase 4 16662-47-8
42
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
43 Tocotrienols Phase 4
44 Neurotransmitter Agents Phase 4
45 Retinol palmitate Phase 4
46 retinol Phase 4
47 Calciferol Phase 4
48 Castor Phase 4
49 Cathartics Phase 4
50 Laxatives Phase 4

Interventional clinical trials:

(show top 50) (show all 867)
# Name Status NCT ID Phase Drugs
1 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
2 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
3 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
4 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
5 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
6 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
7 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
8 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
9 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
10 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
11 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
12 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
13 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
14 Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study Completed NCT03608761 Phase 4 Rebamipide
15 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
16 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
17 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
18 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
19 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
20 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
21 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
22 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
23 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
24 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
25 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
26 Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye Completed NCT04091581 Phase 4 Systane Complete
27 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
28 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
29 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
30 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
31 Evaluation of the Repeated Usage of Systane Ultra Eyedrop Completed NCT01051804 Phase 4
32 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
33 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
34 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
35 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
36 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
37 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
38 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
39 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
40 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
41 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
42 Quality of Life in a Portuguese Population With Primary Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
43 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
44 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
45 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
46 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
47 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
48 A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
49 Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients Completed NCT01311609 Phase 4
50 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4

Search NIH Clinical Center for Sjogren Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


hydroxyethyl cellulose
Linolenic Acid
Sodium Chloride
SODIUM CHLORIDE 0.9% PROCESSING SOLN
SODIUM CHLORIDE GRANULES

Cochrane evidence based reviews: sjogren's syndrome

Genetic Tests for Sjogren Syndrome

Anatomical Context for Sjogren Syndrome

MalaCards organs/tissues related to Sjogren Syndrome:

40
Eye, Salivary Gland, Skin, Testes, Lung, Kidney, Liver

Publications for Sjogren Syndrome

Articles related to Sjogren Syndrome:

(show top 50) (show all 2840)
# Title Authors PMID Year
1
Peripheral neuropathy in primary sjogren syndrome: a population-based study. 56 61
17101831 2006
2
A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. 61 56
15485632 2004
3
Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. 54 56
11247557 2001
4
Regulation of human leukocyte antigen expression in human conjunctival epithelium. 56 61
9888423 1999
5
Ocular complications of primary Sjögren syndrome in men. 56
26093285 2015
6
Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. 56
17071741 2006
7
Vogt-Koyanagi-Harada syndrome and keratoconjunctivitis sicca. 56
15059728 2004
8
In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. 56
12905478 2003
9
Assessing the severity of keratitis sicca with videokeratoscopic indices. 56
12799233 2003
10
Primary Sjögren's syndrome and deficiency of ICA69. 56
12383988 2002
11
Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. 56
11879137 2002
12
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome. 56
11274068 2001
13
Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. 56
11013183 2000
14
Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. 56
6437309 1984
15
Genetic differences between primary and secondary sicca syndrome. 56
314586 1979
16
Familial Sjögren's syndrome with associated primary salivary gland lymphoma. 56
766625 1976
17
Clinical significance of progranulin correlated with serum soluble Oxford 40 ligand in primary Sjögren's syndrome. 42
32358369 2020
18
Elevated EPSTI1 promote B cell hyperactivation through NF-κB signalling in patients with primary Sjögren's syndrome. 42
32114510 2020
19
Gut dysbiosis is prevailing in Sjögren's syndrome and is related to dry eye severity. 42
32059038 2020
20
Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome. 61 54
19657778 2009
21
Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's syndrome. 54 61
19332626 2009
22
ELISA subtypization of anti-ENA autoantibodies in clinical management of autoimmune diseases in Bosnia and Herzegovina. 54 61
20380108 2009
23
Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. 54 61
18617551 2008
24
Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse model for Sjögren's syndrome. 61 54
18696337 2008
25
The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome. 61 54
18612930 2008
26
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. 61 54
18354239 2008
27
A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. 54 61
18480584 2008
28
Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. 54 61
17675493 2007
29
Is SS-A/Ro52 a hydrogen peroxide-sensitive signaling molecule? 54 61
17184176 2007
30
Prognostic value of auto-antibodies in the serum of Omani patients with gastric cancer. 61 54
17143367 2006
31
[Prevalence of antiphospholipid antibodies in patients with primary Sjögren's syndrome]. 61 54
17195353 2006
32
Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. 61 54
16353132 2006
33
Analysis of in vivo role of alpha-fodrin autoantigen in primary Sjogren's syndrome. 54 61
16192640 2005
34
Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. 54 61
16014536 2005
35
Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjogren's syndrome and radiation therapy. 54 61
15740707 2005
36
[Molecular mechanisms of salivary gland destruction in patients with Sjogren's syndrome. ]. 61 54
15744117 2005
37
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. 54 61
15694905 2005
38
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. 61 54
15647194 2005
39
Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome. 61 54
15692983 2005
40
Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. 54 61
15353609 2004
41
Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. 54 61
15448217 2004
42
Character of ocular surface mucins and their alteration in dry eye disease. 54 61
17216084 2004
43
[Abnormal interferon-inducible protein-10 expression in the labial glands of patients with Sjogren's syndrome]. 54 61
14650168 2003
44
Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. 61 54
12887055 2003
45
[Expression of chemokine in the labial glands of patients with Sjogren's syndrome]. 54 61
12812666 2003
46
Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. 54 61
11591123 2001
47
Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome. 61 54
11313424 2001
48
Polymorphisms of the Ro52 gene associated with anti-Ro 52-kd autoantibodies in patients with primary Sjögren's syndrome. 54 61
11263778 2001
49
Sjögren's syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome. 54 61
10674855 2000
50
Amidolytic and peptidolytic activities of immunoglobulin G present in sera from patients with rheumatoid arthritis, Sjogren's syndrome and systemic lupus erythematosus. 61 54
9767453 1998

Variations for Sjogren Syndrome

Expression for Sjogren Syndrome

Search GEO for disease gene expression data for Sjogren Syndrome.

Pathways for Sjogren Syndrome

Pathways related to Sjogren Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Toll-like receptor signaling pathway hsa04620
2 JAK-STAT signaling pathway hsa04630

GO Terms for Sjogren Syndrome

Cellular components related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 LTF IL2RA FASLG FAS APOH

Biological processes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.5 HSPG2 FASLG APOH
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.43 TNFSF13B FASLG FAS
3 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.16 FASLG FAS
4 necroptotic signaling pathway GO:0097527 8.96 FASLG FAS
5 activation-induced cell death of T cells GO:0006924 8.62 IL2RA FAS

Sources for Sjogren Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....